NCT04278092已完成2 期
Paclitaxel Plus Cetuximab for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer After First-line Checkpoint Inhibitor Failure: A Multicenter, Single Arm Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
Immune checkpoint inhibitors (CPI) such as pembrolizumab or nivolumab have been recently approved for the treatment of recurrent/metastatic head and neck cancer (HNSCC). However, only a minority of patients respond to therapy. From the clinical point of view the optimal management of patients progressing on or after CPI therapy is still a challenge. Retrospective analysis showed that HNSCC patients, who progressed on/after CPI, demonstrated an overall response rate (ORR) of up to 30% subsequent to chemotherapy +/- cetuximab treatment. It is the aim of this study to evaluate if paclitaxel plus cetuximab after first line pembrolizumab failure is an effective salvage therapy in 50 R/M HNSCC patients. The primary endpoint is ORR according to RECIST V 1.1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has provided written informed consent prior to any study-related procedure.
- •The patient is at least 18 years of age
- •Histologically proven locally advanced unresectable, recurrent and/or metastatic squamous cell carcinoma of the oropharynx, hypopharynx, larynx or oral cavity not amenable for salvage surgery
- •p16 status has to be determined for oropharyngeal carcinomas
- •Documented progressive disease based on investigator assessment according to RECIST 1.1, following receipt of a pembrolizumab based regimen given as first line therapy for R/M SCCHN
- •Measurable disease according to RECIST 1.
- •The patient has a life expectancy of at least 3 months.
- •Has a performance status of ≤ 2 on the ECOG Performance Scale
- •Female patient of childbearing potential should have a negative urine or serum pregnancy prior to study . If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Female patients of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study until 120 days after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- •Male patients should agree to use an adequate method of contraception starting with the first dose of study therapy until 120 days after the last dose of study therapy.
- •Demonstrate adequate organ function as defined in table 1, all screening labs should be performed within 14 days of treatment initiation.
排除标准
- •Prior taxane therapy is not allowed except as part of induction therapy for locally advanced disease (completed at least 6 months before study entry)
- •Prior cetuximab therapy is not allowed except as part of either induction therapy or in combination with radiotherapy treatment for locally advanced disease (completed at least 6 months before study entry)
- •Patients with nasopharyngeal carcinomas or salivary glands cancers
- •Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatment.
- •Has a diagnosis of immunodeficiency including a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- •Has known active Hepatitis A/B or Hepatitis C
- •Has had prior pembrolizumab within 2 weeks prior to study day 1 or who has not recovered (i.e., recovery to ≤ Grade 1 or baseline grade prior to pembrolizumab) from (immune- related) adverse events other than endocrine side effects.
- •Has had prior chemotherapy or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., recovery to ≤ Grade 1 or baseline grade prior to pembrolizumab) from adverse events due to a previously administered agent.
- •Has had chemotherapy, targeted therapy or investigational drugs after checkpoint inhibitor failure for second line therapy .
- •Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •Has an active infection requiring systemic therapy.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit until 120 days after the last dose of trial treatment.
研究组 & 干预措施
Paclitaxel plus Cetuximab
Experimental
Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
干预措施: Paclitaxel (Drug)
Paclitaxel plus Cetuximab
Experimental
Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
干预措施: Cetuximab (Drug)
结局指标
主要结局
Overall response rate
时间窗: 3 months
To evaluate the Overall Response Rate (CR/PR) rate according to RECIST V 1.1
次要结局
- Median Duration of response(2 years)
- Median Overall Survival(2 years)
- Health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) H&N35 scoring manual(2 years)
- Health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30 scoring manual(2 years)
- Median Progression Free Survival(2 years)
- Number of participants with adverse events(2 years)
研究者
Thorsten Fuereder
Assoc.Prof.
Medical University of Vienna
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNCT05407155Fudan University56
已完成
1 期
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma PatientsInduction ChemotherapyProgrammed Cell Death 1 InhibitorInductive TherapyOral CancerNCT04473716Shanghai Jiao Tong University School of Medicine20
已完成
2 期
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaRenal Cell CarcinomaNCT03297593Swiss Group for Clinical Cancer Research74
进行中（未招募）
1 期
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCTriple Negative Breast CancerNCT03616886Jules Bordet Institute129
进行中（未招募）
1 期
Paclitaxel plus cetuximab for the treatment of recurrentand/or metastatic head and neck cancer after first-line checkpointinhibitor failure: A multicenter, single arm studyEUCTR2019-003114-13-ATMed. Univ. Wien, Klinik f. Innere Med. I, Onkologie50